New York Attorney General Letitia James is set to collect more than $29 million from Glenmark Pharmaceuticals, after her office and a bipartisan squad of state attorneys general cut a deal with the drugmaker over what they say was an illegal scheme to jack up prices on generic medications.
The money, flagged in recent corporate filings, is supposed to flow back to consumers and public health programs that paid inflated prices for everyday medicines. It is the latest chapter in a sprawling multistate investigation that has already produced several settlements with generic manufacturers.
As New York Attorney General Letitia James wrote on X, “Affordable generic drugs are a lifeline for New Yorkers with heart conditions, diabetes, and other chronic illnesses.” New York Attorney General Letitia James said her office and a bipartisan coalition had “secured over $29 million” from Glenmark as part of the wide‑ranging probe.
Glenmark's disclosure and the money
Glenmark revealed in a May regulatory filing that its U.S. arm agreed to settle with state attorneys general for a total of $29.628 million, to be paid out in annual installments over five years, with the deal still awaiting court approval. Glenmark Pharmaceuticals states in the filing that it denies the civil allegations and that the settlement does not amount to an admission of liability.
Federal prosecution and the broader case
Before the state settlement talks heated up, the company had already entered a deferred prosecution agreement with the U.S. Department of Justice, in which it admitted to taking part in a conspiracy to fix prices for the cholesterol drug pravastatin and agreed to pay a $30 million criminal penalty, according to the department. U.S. Department of Justice officials have said those criminal resolutions were part of a broader sweep that uncovered collusion across the generic drug industry.
Who could get money back
The state lawsuits accuse multiple companies of coordinated price‑fixing, market allocation, and bid‑rigging across dozens of generic drugs. Earlier settlements in the same litigation have steered restitution back to both individual consumers and government health programs. New York Attorney General's Office materials urge New Yorkers who purchased certain generic prescriptions between May 2009 and December 2019 to sign up for potential compensation.
What happens next
The Glenmark deal now heads to the court overseeing the consolidated litigation, which must sign off before any checks start going out. If approved, the payments will roll out on the agreed‑upon schedule. Glenmark Pharmaceuticals notes in its filing that it has already reserved the full settlement amount in its financial statements and does not expect the agreement to have a material impact on its finances.
The wider case is still very much alive, and attorneys general say they plan to keep pressing generic manufacturers to return money to consumers and taxpayer‑funded health programs they believe were overcharged.
